Pump delivery of hormone may steady calcium levels in rare disorder

NCT ID NCT00743782

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two ways of delivering synthetic parathyroid hormone (PTH) to people with chronic hypoparathyroidism, a condition where the body doesn't make enough PTH, causing low calcium. Researchers compared using an insulin pump to give steady, small doses versus twice-daily injections. The goal was to see if the pump could keep blood and urine calcium levels more stable, mimicking natural hormone release. The trial included 21 adults and children with different forms of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
synthetic human parathyroid hormone (PTH 1-34)
What this could lead to
If successful, this could offer a more convenient and effective way to manage hypoparathyroidism, reducing daily fluctuations in calcium levels.
What could go wrong
This is a small, early-phase study with only 21 participants, so results may not apply to everyone. The pump method may not work better or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.